Max Planck Society

World's Leading Award for Animal Conservation Names Six Finalists

Retrieved on: 
星期三, 三月 1, 2023
Indianapolis Prize, DVM, Public health, Conservation Through Public Health, Orangutan Foundation International, News, Gala, Internet, Indianapolis Zoo, Chimpanzee, NBC News, National Autonomous University, Winner, Max Planck Society, Science, Animal, Cummins, Whaling, Hunting, Ecology

INDIANAPOLIS, March 1, 2023 /PRNewswire/ -- The Indianapolis Zoological Society Inc., the presenter of the world's leading award for animal conservation, today named the six Finalists for the Indianapolis Prize, an award that recognizes the most successful conservationists who have achieved major victories in saving an animal species or group of species. This biennial award provides the Winner with $250,000 and the remaining Finalists with $50,000 each.

Key Points: 
  • INDIANAPOLIS, March 1, 2023 /PRNewswire/ -- The Indianapolis Zoological Society Inc., the presenter of the world's leading award for animal conservation, today named the six Finalists for the Indianapolis Prize, an award that recognizes the most successful conservationists who have achieved major victories in saving an animal species or group of species.
  • This biennial award provides the Winner with $250,000 and the remaining Finalists with $50,000 each.
  • A nine-person committee with ties to the scientific and conservation communities, the Indianapolis Zoological society and local community selected the six Finalists for the 2023 Indianapolis Prize.
  • "The vital work of this year's Finalists to save animal species is inspiring," said 2021 and 2023 Indianapolis Prize Gala co-host Danni Washington.

The European Gauss Fusion Initiative Seeks to Use Magnetic Fusion to Ensure a Clean and Safe Energy Supply

Retrieved on: 
星期二, 二月 28, 2023
Research, Other Energy, Professional Services, Utilities, Nuclear, Alternative Energy, Energy, Environment, Green Technology, Science, Finance, Other Science, Safety, KIT, United States Air Force Scientific Advisory Board, PPP, Life, Maintenance, Partnership, German, Karlsruhe Institute of Technology, Max Planck Institute for Plasma Physics, Sun, Max Planck Society, Education, Federal Ministry of Science, Technology and Innovation, Plasma, IPP, Acceleration, Wind, Advisory board, Multimedia, CERN, Federal, Renewable energy, Lithium, European, EU

View the full release here: https://www.businesswire.com/news/home/20230227005883/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230227005883/en/
    Gauss Fusion wants to provide energy security for future generations by establishing fusion power as a safe and clean source of energy (source: Adobe Stock/Banana Images – stock.adobe.com)
    The Gauss Fusion Initiative has set itself the goal of bringing the first European GW-class (electric) fusion power plant (Gauss GIGA fusion power plant) on stream by 2045.
  • Gauss Fusion now offers support to this process, which has the potential to accelerate the development of clean fusion energy generation “at venture speed” thanks to efficient structures.
  • Gauss Fusion is a proponent of an entrepreneurial path to a considerable acceleration of fusion energy in a close “public-private partnership” (PPP) with national and European institutions.
  • In addition, we expect leading partners from the energy industry to join the Gauss Fusion initiative in the near future.”

Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer

Retrieved on: 
星期一, 一月 9, 2023
NYU Langone Health, Veterinary medicine, University, Therapy, Max Planck Society, Nestlé, AstraZeneca, University Medical Center, Medicine, RNA, Toxicology, MBA, Doctor of Philosophy, University of Helsinki, Pharmaceutical industry

SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company.

Key Points: 
  • SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company.
  • "I am thrilled to join Ractigen as the Company prepares to initiate clinical studies in multiple indications," said Dr. Järveläinen.
  • Prior to joining Ractigen, Dr. Järveläinen built and transformed a San Diego -based academic startup into a clinical-stage biotech Cend Therapeutics, with the lead product CEND-1 now being tested in multiple mid-to-late-stage clinical trials.
  • During his 20-year pharmaceutical industry career, Dr. Järveläinen has held various progressively senior-level roles at AstraZeneca, Nestle and Pharmaron.

BiondVax CEO Issues Letter to Shareholders

Retrieved on: 
星期五, 十二月 30, 2022
PEI, Non-governmental organization, Infection, GMP, Neutralizing antibody, Drug development, BVXV, Failure, Macular degeneration, Contraindication, Max Planck, Pfizer, VHH, COVID-19, SARS-COV-2, Lead, Optimism, European Investment Bank, Risk, Comorbidity, Creativity, CDMO, Mab, MPI, Growth, Patient, Degenerative disease, Letter, Exercise, Collaboration, Omicron, Consultant, Paul Ehrlich Institute, Safety, Max Planck Society, Therapy, UMG, Psoriasis, BiondVax, EIB, Life, University Medical Center, Asthma, Library, Vaccine, Caregiver, Pharmaceutical industry, Risk management, Fine chemical

The letter reads as follows:

Key Points: 
  • The letter reads as follows:
    BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.
  • As compared to mAbs, NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages.
  • We reported the successful first readout results in the preclinical in vivo study of our innovative inhaled COVID-19 NanoAb therapy.
  • I also want to thank our shareholders for their continued support as we progress toward our objectives.

IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
星期二, 十二月 13, 2022
Asthma, BVXV, Weizmann Institute of Science, Degenerative disease, IBN, Glatiramer acetate, University Medical Center, Season, DBP, News, Knowledge, Drug Quality and Security Act, Psoriasis, Infection, Research, Teva Pharmaceuticals, History, Social media, Reichmann, COVID-19, Max Planck Society, Pharmaceutical industry, BiondVax

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.

Key Points: 
  • The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.
  • Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.
  • The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series .
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Sensei Biotherapeutics Provides Update on Strategic Priorities

Retrieved on: 
星期四, 十二月 8, 2022
Max Planck Institute of Biochemistry, CD39, Investigational New Drug, Concluding observations on the second periodic report of the Holy See, Ludwig Maximilian University of Munich, Neoplasm, Max Planck Society, Tumor microenvironment, Amgen, Biochemistry, Chemistry, Daiichi Sankyo, Max Planck Institute of Neurobiology, FDA, Safety, Cancer, VISTA, Doctor of Philosophy, Schmidt Science Fellows, Workforce, Research, IND, Risk, OncoMed, ...Continued, Patient, Therapy, Vaccine, Pharmaceutical industry, Management, Sensei

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- eSensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.

Key Points: 
  • Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site.
  • “Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones.
  • Prior to joining Sensei in 2019, Dr. van der Horst worked at Zenith Epigenetics Ltd., Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo).
  • Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

Retrieved on: 
星期二, 十二月 6, 2022
Creativity, Article (publishing), LMU, Associate, Asthma, Head, BVXV, Coronavirus, Immunology, Weizmann Institute of Science, Annual report, Degenerative disease, VHH, Communication, Neutralizing antibody, University Medical Center, Security (finance), SAB, The EMBO Journal, Centre for Journalism (University of Southern Denmark), Motivation, Cancer, Princeton University, Psoriasis, Drug development, Macular degeneration, Infection, Virology, Research, Professor, Severe acute respiratory syndrome coronavirus 2, BiondVax, Risk, Professional, University, COVID-19, UMG, Therapy, Max Planck Society, Pharmaceutical industry

Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).

Key Points: 
  • Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).
  • Professor Dobbelstein has served as Director of the Institute of Molecular Oncology at the University Medical Center Göttingen (UMG), Germany since 2005 and is also an Associate Member of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • In addition, Professor Dobbelstein, together with Professor Görlich, is collaborating with BiondVax under a five-year strategic research agreement for the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.
  • Professor Ruth Arnon, head of BiondVax’s SAB and The Paul Ehrlich Professor of Immunology at the Weizmann Institute of Science, Israel, commented, “We are pleased to welcome Matthias’ broad and relevant expertise to BiondVax’s SAB.

BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
星期三, 十一月 30, 2022
COVID-19, Degenerative disease, Weight loss, Inhalation, University Medical Center, BiondVax, BVXV, MPG, UMG, SARS-COV-2, Max Planck Society, Animal, Infection, Pharmaceutical industry

JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the quarter ended Sept. 30, 2022, and provided a business update.

Key Points: 
  • JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the quarter ended Sept. 30, 2022, and provided a business update.
  • As previously reported , BiondVax has received notice of non-compliance with Nasdaq listing rules regarding minimum Shareholders Equity and minimum share bid price.
  • This by itself brought the shareholders value to above the minimum threshold to meet Nasdaq requirements as of Sept. 30, 2022.
  • Unaudited third quarter financial results will be submitted to the Securities and Exchange Commission on Form 6-K. A summary is included in the tables below.

Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases

Retrieved on: 
星期一, 十一月 28, 2022
Research, Pharmaceutical, Robotics, Mental Health, Medical Devices, Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, FDA, Health, PrimeSense, Compound, Magnetism, Khosla Ventures, Use, Engineering, Prevalence, Max Planck Institute for Experimental Medicine, IND, Safety, Brain, Facial recognition, Toxicity, Neuroscience, Ageing, Neurodegeneration, 3D, Pectus carinatum, Central nervous system, Deep Insight, Drug development, OurCrowd, CNS, Face ID, IDE, Hydrocephalus, Revolution, Max Planck Society, Robotics, BNL, Therapeutic index, Huntington's disease, Therapy, Venture, Traffic barrier, Biology, Glioma, FDA, Medical device, Pharmaceutical industry, Medical imaging, Labs, Apple

By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.

Key Points: 
  • By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.
  • Funds will be used to advance clinical development of the companys lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder).
  • Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough.
  • We are extremely excited about the transformative potential Bionaut presents in treating debilitating neurological disorders, said Vinod Khosla, founder of Khosla Ventures.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
星期日, 十一月 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.